Related Experiment Videos
Tuberculosis and human immunodeficiency virus infection in west Burkina Faso: clinical presentation and clinical
J E Malkin1, T Prazuck, F Simonnet
1Université Paris XII, Service des Maladies Infectieuses, Centre Hospitalier, Villeneuve Saint Georges, France.
Objective:
To study the relationship between human immunodeficiency virus (HIV) infection and tuberculosis (TB) in a West African country.
Design:
A cohort study in TB patients at the TB centre of Bobo Dioulasso, Burkina Faso.
Results:
HIV seroprevalence rose from 12.5% in 1987 to 24.7% in 1990. Analysis of clinical findings showed that extra-pulmonary TB was not more frequent in HIV-positive patients (18.5%) than in HIV negative patients (17.3%). Four symptoms were independently associated with HIV infection: diarrhoea, lymphadenopathy, weight loss and oral candidiasis. At the end of six months of chemotherapy for TB (2SHRZ/4HR), the mortality rate among HIV-positive TB patients was 27%, versus 10% among HIV-negative TB patients (P < 0.001). There was no difference between treatment failure rates among HIV-positive patients (3.8%) and HIV-negative patients (3.9%). At the final evaluation, 18 months after the start of chemotherapy, the relapse rate was 8% in HIV-positive patients versus 5.6% in HIV-negative patients (NS). Global mortality rate during the whole study period was significantly higher in HIV-1 (40.3%) and HIV-1 + 2 (20%) patients than in HIV-2 (11.1%) and HIV-negative (12.9%) patients.
Conclusion:
We conclude that, according to previous African studies, despite a higher mortality rate due generally to HIV disease itself, short-course chemotherapy of 6 months is as effective in HIV-positive patients as in HIV-negative patients, and must be continued.